Adverse events associated with hormonal therapy for prostate cancer
about
Androgen deprivation therapy in the treatment of advanced prostate cancerThe role of physical rehabilitation in stem cell transplantation patientsEfficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Impact of androgen deprivation therapy on sexual functionSex hormones in gender-specific risk for head and neck cancer: A reviewImpact of age at diagnosis on prostate cancer treatment and survivalLarge pseudoangiomatous stromal hyperplasia complicated with gynecomastia and lobular differentiation in a male breast.Men with cancer change their health behaviour: a prospective study from the Danish diet, cancer and health studyLeuprorelin depot injection: patient considerations in the management of prostatic cancerCognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.Adverse effects of androgen deprivation therapy for prostate cancer: prevention and managementAssociation of Androgen Deprivation Therapy With Depression in Localized Prostate CancerDevelopment and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment.Somatic mutations in salivary duct carcinoma and potential therapeutic targets.Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approachThe Effect of Relaxation Technique on Fatigue Levels after Stem Cell Transplant
P2860
Q24676531-F812FB80-659A-41A0-970F-6050BC5613FEQ28087720-E4091B21-7C86-40F1-9BD4-0B9DF1E5BA73Q33647728-45B519DF-0343-4E64-B16F-C40B327692FEQ33897252-4E4744BE-D30A-4ADE-9DD3-F0BC1785C12DQ34245932-BEBCEB64-9226-477A-B105-3EA9B113360AQ34586321-1749F791-A39B-419D-8EBC-8C5D584F2289Q34679220-72ED743C-0925-4681-8F40-2F1E77DDDB5DQ35756636-0762490F-17C3-42C5-89C5-202D632E338EQ36075294-61BDBED4-3F53-4C2D-BDA9-86B387DB2603Q36823588-CD354009-C5D2-4376-9996-42B46B0F94A9Q36834837-C59F5991-154D-4FF0-95BD-3A5F3F1F85D1Q37105407-EB72FDCE-9DCB-40FE-9341-7D007314F740Q37137956-9FDC7BAC-4A16-4599-84C4-CA8257CCDE67Q42425144-102481F5-E69A-4539-A74C-F1BB14714DD8Q47133482-D0FFCBCD-79A1-4DA3-8654-2751BB44CBF8Q49466230-42013890-0EBE-4662-8677-953A6B87B1BBQ57108196-B63BFA46-6751-4731-8DD0-50731A5C616EQ58777478-2D6DFD28-8D48-4D28-8B73-552AE789D831
P2860
Adverse events associated with hormonal therapy for prostate cancer
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Adverse events associated with hormonal therapy for prostate cancer
@ast
Adverse events associated with hormonal therapy for prostate cancer
@en
Adverse events associated with hormonal therapy for prostate cancer
@nl
type
label
Adverse events associated with hormonal therapy for prostate cancer
@ast
Adverse events associated with hormonal therapy for prostate cancer
@en
Adverse events associated with hormonal therapy for prostate cancer
@nl
prefLabel
Adverse events associated with hormonal therapy for prostate cancer
@ast
Adverse events associated with hormonal therapy for prostate cancer
@en
Adverse events associated with hormonal therapy for prostate cancer
@nl
P2093
P2860
P1433
P1476
Adverse events associated with hormonal therapy for prostate cancer
@en
P2093
Al Barqawi
E David Crawford
Ravi J Kumar
P2860
P304
P407
P478
P577
2005-01-01T00:00:00Z